Circle Pharma to Participate in Upcoming Investor Conferences

Audio By Carbonatix

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Sep 2, 2025--

Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for difficult-to-treat cancers, today announced that management will participate in two upcoming investor conferences:

Morgan Stanley 23rd Annual Healthcare Conference
1X1 Meetings: Monday, September 8, 2025
Location: New York, NY

Oppenheimer Life Sciences Private Company Showcase
1X1 Meetings: Thursday, September 25, 2025
Location: Virtual

About Circle Pharma

Circle Pharma is a clinical-stage biopharmaceutical company harnessing the power of macrocycles to develop next-generation targeted therapies for cancer and other serious illnesses. The company’s proprietary MXMO™ platform overcomes key challenges in macrocycle drug development, enabling the creation of intrinsically cell-permeable and orally bioavailable therapies, including for historically undruggable targets. Circle Pharma’s pipeline is focused on targeting cyclins, key regulators of the cell cycle that drive many cancers. The company’s lead program, CID-078, is a cyclin A/B RxL inhibitor in Phase 1 clinical development for patients with advanced solid tumors. Circle Pharma is based in South San Francisco, CA. For additional information, please visit us at circlepharma.com and follow us on LinkedIn and X.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250901920901/en/

CONTACT: Media:

Josie Butler

1AB

[email protected]:

Steve Klass

1AB

[email protected]

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA NEW YORK

INDUSTRY KEYWORD: PROFESSIONAL SERVICES ONCOLOGY HEALTH VENTURE CAPITAL PHARMACEUTICAL BIOTECHNOLOGY

SOURCE: Circle Pharma, Inc.

Copyright Business Wire 2025.

PUB: 09/02/2025 08:00 AM/DISC: 09/02/2025 07:59 AM

http://www.businesswire.com/news/home/20250901920901/en